[go: up one dir, main page]

MX388300B - Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato - Google Patents

Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato

Info

Publication number
MX388300B
MX388300B MX2019011844A MX2019011844A MX388300B MX 388300 B MX388300 B MX 388300B MX 2019011844 A MX2019011844 A MX 2019011844A MX 2019011844 A MX2019011844 A MX 2019011844A MX 388300 B MX388300 B MX 388300B
Authority
MX
Mexico
Prior art keywords
preparation
formula
compounds
acid derivatives
bile acid
Prior art date
Application number
MX2019011844A
Other languages
English (en)
Other versions
MX2019011844A (es
Inventor
Brett Granger
Guoqiang Wang
Xuechao Xing
Yat Sun Or
Yong He
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2019011844A publication Critical patent/MX2019011844A/es
Publication of MX388300B publication Critical patent/MX388300B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con procesos para la preparación de compuestos de la Fórmula (I) y compuestos de la Fórmula (II): o un solvato o sal farmacéuticamente aceptable del mismo. Estos compuestos y composiciones farmacéuticas son útiles como moduladores de FXR o TGR5. Específicamente, la presente invención se refiere a derivados de ácidos biliares y métodos para su preparación y uso. La presente invención se refiere a un proceso para la preparación de los compuestos de la Fórmula (III), Fórmula (IV), Fórmula (V) y Fórmula (VI), La presente invención también se refiere a un proceso para la preparación de los compuestos (VII), (VIII) y (IX),
MX2019011844A 2017-04-07 2018-04-09 Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato MX388300B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483044P 2017-04-07 2017-04-07
PCT/US2018/026696 WO2018187804A1 (en) 2017-04-07 2018-04-09 Process for preparation of sulfonyl carbamate bile acid derivatives

Publications (2)

Publication Number Publication Date
MX2019011844A MX2019011844A (es) 2021-11-30
MX388300B true MX388300B (es) 2025-03-19

Family

ID=63710729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011844A MX388300B (es) 2017-04-07 2018-04-09 Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato

Country Status (12)

Country Link
US (2) US10676500B2 (es)
EP (1) EP3606533B1 (es)
JP (1) JP7136802B2 (es)
KR (1) KR102624997B1 (es)
CN (1) CN110612105B (es)
AU (1) AU2018249950B2 (es)
BR (1) BR112019020780A2 (es)
CA (1) CA3058754A1 (es)
ES (1) ES2971092T3 (es)
IL (1) IL269859B2 (es)
MX (1) MX388300B (es)
WO (1) WO2018187804A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
BR112017010893A2 (pt) 2014-11-26 2018-02-06 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
MY192135A (en) 2015-03-31 2022-07-29 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
JP7057783B2 (ja) 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニル尿素胆汁酸誘導体の調製方法
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN112341512A (zh) * 2020-04-13 2021-02-09 苏州恩泰新材料科技有限公司 由海豹胆酸制备鹅去氧胆酸的方法
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592791A (en) 1977-01-07 1981-07-08 Radiochemical Centre Ltd Selenium- or tellurium-containing bile acids and derivatives thereof
WO1987002367A2 (en) 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
IT1255485B (it) 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica
TW289020B (es) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289757B (es) 1993-05-08 1996-11-01 Hoechst Ag
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
US5646316A (en) 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
JPH1160594A (ja) 1997-08-25 1999-03-02 Sankyo Co Ltd 胆汁酸誘導体
JP3865890B2 (ja) 1997-09-30 2007-01-10 富士フイルムホールディングス株式会社 ポジ型感光性組成物
EP1140079B1 (en) 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
ATE442360T1 (de) 2000-07-26 2009-09-15 Us Gov Health & Human Serv 5-substituierte pyrimidinderivate eines konformatiosfestgelegten nukleosidanalogen
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
ITMI20021080A1 (it) 2002-05-21 2003-11-21 Marcello Izzo Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ES2533993T3 (es) 2004-03-12 2015-04-16 Intercept Pharmaceuticals, Inc. Tratamiento de fibrosis usando ligandos de FXR
US20090192077A1 (en) 2005-04-15 2009-07-30 Shizuko Sei North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101378761B (zh) 2006-02-01 2013-10-16 杨百翰大学 阳离子类固醇抗微生物剂组合物及其使用方法
EP1987051A2 (en) 2006-02-14 2008-11-05 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
WO2007111994A2 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
CA2656320C (en) 2006-06-27 2015-04-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
EP2044100A2 (en) 2006-07-17 2009-04-08 Novartis AG Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
BRPI0808684B1 (pt) 2007-01-19 2021-08-10 Intercept Pharmaceuticals, Inc Compostos moduladores de tgr5, composição e seus usos
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
CA2922021C (en) 2007-09-06 2018-01-09 Ohr Pharmaceutical, Inc. A method for treating diabetes
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
KR101239008B1 (ko) 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP2014521699A (ja) 2011-08-04 2014-08-28 ルメナ ファーマシューティカルズ，インク． 膵臓炎の処置用の胆汁酸再利用阻害剤
WO2013043554A1 (en) 2011-09-23 2013-03-28 Access Business Group International Llc Methods for creating recommended dietary regime
WO2013049595A1 (en) 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
HK1211296A1 (en) 2012-06-19 2016-05-20 英特塞普特医药品公司 Preparation, uses and solid forms of obeticholic acid
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
WO2014036379A2 (en) 2012-08-31 2014-03-06 Metselex Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
MX352065B (es) 2013-05-14 2017-11-08 Intercept Pharmaceuticals Inc Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoidex.
AU2014296023B2 (en) 2013-08-01 2020-02-06 The Penn State Research Foundation Inhibitors of the farnesoid X receptor and uses in medicine
WO2015061421A1 (en) 2013-10-22 2015-04-30 Metselex, Inc. Deuterated bile acids
AU2015265893B2 (en) 2014-05-29 2020-11-12 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法
CN105669811B (zh) * 2014-11-17 2020-09-04 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US20160176917A1 (en) 2014-11-26 2016-06-23 Enanta Pharmaceuticals, Inc. Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
BR112017010893A2 (pt) 2014-11-26 2018-02-06 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MY192135A (en) 2015-03-31 2022-07-29 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN106083978A (zh) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
WO2016173397A1 (zh) 2015-04-28 2016-11-03 上海翰森生物医药科技有限公司 胆酸衍生物及其制备方法和医药用途
CN111574577B (zh) 2015-04-29 2025-02-25 正大天晴药业集团股份有限公司 鹅去氧胆酸衍生物
CN107771180B (zh) 2015-06-19 2021-03-23 英特塞普特医药品公司 Tgr5调节剂及其使用方法
CN108137643A (zh) 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
CN105175473B (zh) 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
AU2016325619A1 (en) 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
MA42339A1 (fr) 2015-10-07 2019-01-31 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
MX391812B (es) 2016-01-28 2025-03-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Agonista fxr derivado de esteroides.
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
ES2874682T3 (es) 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
JP7057783B2 (ja) 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニル尿素胆汁酸誘導体の調製方法
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives

Also Published As

Publication number Publication date
JP2020512994A (ja) 2020-04-30
US10961272B2 (en) 2021-03-30
MX2019011844A (es) 2021-11-30
IL269859A (en) 2019-11-28
BR112019020780A2 (pt) 2020-04-28
CN110612105B (zh) 2023-05-02
ES2971092T3 (es) 2024-06-03
US20200317717A1 (en) 2020-10-08
EP3606533A4 (en) 2021-05-26
KR20200010215A (ko) 2020-01-30
RU2019135044A (ru) 2021-05-07
WO2018187804A1 (en) 2018-10-11
JP7136802B2 (ja) 2022-09-13
AU2018249950A1 (en) 2019-11-07
CN110612105A (zh) 2019-12-24
EP3606533A1 (en) 2020-02-12
CA3058754A1 (en) 2018-10-11
US20180291058A1 (en) 2018-10-11
US10676500B2 (en) 2020-06-09
EP3606533B1 (en) 2023-11-15
AU2018249950B2 (en) 2023-09-21
RU2019135044A3 (es) 2021-12-29
KR102624997B1 (ko) 2024-01-12
IL269859B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX388300B (es) Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
MX2020007265A (es) Derivados de rapamicina.
TN2018000106A1 (en) Farnesoid x receptor modulators
CY1120273T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση φαρνεσοειδων υποδοχεων χ
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
PH12017500914A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
PH12016501440A1 (en) Novel heterocyclic compounds
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
HK1243930A1 (zh) 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MA43066A (fr) Procédés de préparation d'acides biliaires et de leurs dérivés
AU2018253590A1 (en) Imidazopyridazine compounds
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2